Hørsholm,
ExpreS[2]ion and its joint venture partner AdaptVac are engaged in the development of a unique capsid virus-like particle (VLP) COVID-19 vaccine. In this Horizon 2020 EU-sponsored PREVENT-nCoV program ExpreS[2]ion recently (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-selection-of-agc-biologics-as-manufacturing-partner-for-the-covid-19-vaccine-an,c3094798) announced its ability to produce the SARS-CoV-S2 protein antigen with sufficient purity and quality for animal testing and further continuation of the rapid development towards clinical studies before the end of 2020.
Since the beginning of the vaccine program, the ExpreS[2]-made antigen has been in demand from a variety of groups worldwide. In compliance with the WHO (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-s-cso-dr--wian-de-jongh-co-signs-who-sanctioned-statement-from-83-covid-19-vaccine-resear,c3088606)'s pledge to strengthen worldwide collaboration, cooperation and sharing of data in the scientific community (see WHO statement (https://www.who.int/news-room/detail/13-04-2020-public-statement-for-collaboration-on-covid-19-vaccine-development)), ExpreS[2]ion is also committing to support research and development projects that are synergistic to the current COVID-19 vaccine focus. Most recently ExpreS[2]ion is engaged in an on-going COVID-19 diagnostic test program that Rigshospitalet,
Rigshospitalet's Professor of Clinical Molecular Medicine Dr.
"I am leading a team of experts that focus on bringing a quick and accurate antibody test for COVID-19 as fast as possible to the general public in
ExpreS[2]ion's CEO
"I find it very encouraging that our unique SARS-CoV-2 antigen can be used even beyond the COVID-19 vaccine program. Of the multiple R&D projects we support in this field, I find it especially motivating that a diagnostic test also can be developed by the ExpreS[2] platform. It will be exciting to follow the progression of
The COVID-19 Coronavirus outbreak
A novel Coronavirus (COVID-19) outbreak was reported in
Rigshospitalet's Centre of Diagnostic Investigation
The Centre (https://www.rigshospitalet.dk/english/departments/centre-of-diagnostic-investigation/about-us/Pages/about-the-centre-of-diagnostic-investigation.aspx) is a collection of highly specialised departments working with laboratory analyses including image diagnostics, biochemistry, genetics, microbiology, pathology, immunology, blood donation, blood products and biobanking as well as providing medical advice to clinicians. The research ranges from patient-focused clinical research to molecular biological studies of disease processes.
Certified Adviser
Telephone: +46 70 755 95 51
E-mail: ca@skmg.se
For further information about ExpreS[2]ion
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
About ExpreS[2]ion
ExpreS[2]ion
https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-supporting-an-advantageous-covid-19-diagnostic-antibody-development-project,c3102671
https://mb.cision.com/Main/14402/3102671/1240712.pdf
(c) 2020 Cision. All rights reserved., source